Short answer
Amgen (AMGN) filed its Q1 2025 10-Q quarterly report on May 2, 2025 for the quarter ended Mar 31, 2025. Quarterly revenue was $8.1B (up 9.4% year over year) with net income of $1.7B.
Q1 2025 key financials · XBRL
- Revenue
- $8.1B
- +9.4% YoY
- Net income
- $1.7B
- +1631.0% YoY
- Operating margin
- 14.5%
- EPS (diluted)
- $3.20
- +1623.8% YoY
Source: XBRL data from the Amgen (AMGN) Q1 2025 10-Q on SEC EDGAR. USD.
Amgen Q1 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue Prolia $1,099M, up 10% YoY from $999M
- U.S. Prolia sales $720M up 10%, ROW $379M up 11%
- Global Prolia volume growth 13%, net selling price down 5%
- No profitability or margin data disclosed in this section
- No cash flow or guidance updates mentioned in this excerpt
Risk Factors
- New credit market risk triggered by COVID-19 and interest rate increases causing volatility and potential impairments in investment portfolio
- Market risk materially updated: asset impairments possible from inflation, credit downgrades, illiquidity, geopolitical events affecting investment values
- Regulatory risk: cash deposits exceed insured limits at multinational banks, risking access to uninsured funds if institutions fail
- Operational risk near-term: potential delays accessing uninsured cash could affect liquidity and financial position
- Financial risk: exposure to impairments and realized losses on investments due to market disruptions and interest rate fluctuations
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amgen quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.